Complement activation and altered fibrin clot properties in obstetric antiphospholipid syndrome: impact on thromboembolism and pregnancy
Clinical Rheumatology · 2026
DOI: 10.1007/s10067-026-07927-0 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Rheumatology, 2026. Verfasst von Magdalena Piróg und 4 weiteren Autor:innen. Beteiligte Einrichtung: Gynecological Endocrinology Department, Jagiellonian University Medical College, Ul. Kopernika 23, 31-501, Krakow, Poland. magda.m.pulka@gmail.com. Hauptthemen laut MEDLINE: Antiphospholipid Syndrome, Fibrin, Complement Activation, Complement C5a. Die Arbeit nennt 43 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Prothrombotic fibrin clot properties and increased thrombin generation were observed in obstetric antiphospholipid syndrome (OAPS), but the role of complement in the prothrombotic state is unclear. OBJECTIVES: This study aimed to determine whether circulating C5a and C5b-9 levels are associated with fibrin clot phenotype and thrombin generation in women with OAPS, and to assess their prognostic value for thrombotic events and obstetric outcomes during long-term follow-up. METHODS: In this retrospective study, in 57 women with OAPS, and 57 controls matched for age, weight, and the type of obstetric complications complement components including C5a and C5b-9 levels, along with endogenous thrombin potential (ETP), plasma fibrin clot permeability (KS) and clot lysis time (CLT) were determined at baseline. During a median follow-up of 54 months venous/arterial TE and live births were recorded. RESULTS: OAPS patients compared to controls had higher circulating C5a (+ 95.7%) and C5b-9 (+ 44.8%; both p < 0.05), that were positively associated with IgG anticardiolipin, anti-ß-2-glycoprotein I, and antiphosphatidylserine/prothrombin antibodies. Elevated C5a and C5b-9 correlated with reduced clot permeability (KS, r = -0.42 and r = -0.63), prolonged CLT (r = 0.27 and r = 0.48), and higher thrombin generation (ETP, r = 0.33 and r = 0.39, respectively). Women with higher baseline C5a and C5b-9 (per 1 unit; OR = 0.79, 95% CI: 0.65-0.95, p = 0.013 and OR = 0.98, 95% CI: 0.97-0.99, p = 0.003, respectively) had a lower odd of experiencing pregnancy failure (n = 26, 45.6%). CONCLUSION: Determination of complement components along with fibrin clot properties may be helpful to differentiate women with OAPS with a greater risk of negative pregnancy outcomes. Key Points • Enhanced complement activation with increased thrombin generation and prothrombotic fibrin clot phenotype is observed in women with OAPS. • Higher C5a and C5b-9 in women with OAPS are observed in women with lower chances of live births during follow-up.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Gynecological Endocrinology Department, Jagiellonian University Medical College, Ul. Kopernika 23, 31-501, Krakow, Poland. magda.m.pulka@gmail.com.
- Department of Thromboembolic Disorders, Institute of Cardiology, Jagiellonian University Medical College, Krakow, Poland.
- Krakow Centre for Medical Research and Technologies, St. John Paul II Hospital, Krakow, Poland.
- Gynecological Endocrinology Department, Jagiellonian University Medical College, Ul. Kopernika 23, 31-501, Krakow, Poland.
Zitieren
APA
Piróg, M., Ząbczyk, M., Natorska, J., Jach, R., & Undas, A. (2026). Complement activation and altered fibrin clot properties in obstetric antiphospholipid syndrome: impact on thromboembolism and pregnancy. Clinical Rheumatology. https://doi.org/10.1007/s10067-026-07927-0
Vancouver
Piróg M, Ząbczyk M, Natorska J, Jach R, Undas A. Complement activation and altered fibrin clot properties in obstetric antiphospholipid syndrome: impact on thromboembolism and pregnancy. Clinical Rheumatology. 2026. doi:10.1007/s10067-026-07927-0
BibTeX
@article{Pirg2026,
author = {Piróg, Magdalena and Ząbczyk, Michał and Natorska, Joanna and Jach, Robert and Undas, Anetta},
title = {Complement activation and altered fibrin clot properties in obstetric antiphospholipid syndrome: impact on thromboembolism and pregnancy},
journal = {Clinical Rheumatology},
year = {2026},
doi = {10.1007/s10067-026-07927-0}
}
EUVIMED